人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片 BrainCancer qBiomarker Mutation PCR Array

科技服務(wù) > PCR芯片實驗服務(wù) > 人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片 BrainCancer qBiomarker Mutation PCR Array

人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片 BrainCancer qBiomarker Mutation PCR Array

人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片 Brain Cancer qBiomarker Mutation PCR Array
運費 ￥0.00
（庫存 9999 件）
簡介：Brain Cancer qBiomarker Mutation PCR Array 人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片
提供商：SABio
服務(wù)名稱：人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片
地區(qū)：美國

“英拜為您實驗加速”
技術(shù)服務(wù)網(wǎng)址：http://m.bhsflw.cn/
服務(wù)熱線：400-696-6643、 18019265738
郵箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Brain Cancer qBiomarker Mutation PCR Array

人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片 
ProductSpeciesTechnologyCat. No.
Brain Cancer qBiomarker Mutation PCR ArrayHumanSomatic MutationSMH-025A
The Human Brain (GBM/CNS) Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the top somatic mutations in human GBM/CNS cancer in the following genes: BRAF, CTNNB1/beta-catenin, EGFR, IDH1, IDH2, KRAS, NF2, NRAS, PIK3CA, and PTEN. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions.For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human GBM/CNS Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in the context of GBM/CNS cancers and has the potential for discovery and verification of drug target biomarkers for these cancer types and other cancer types in which these mutations have been identifiedThis array includes 37 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human GBM/CNS cancers.These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 7800 CNS cancer samples (including 6850 glioma samples).Each 96-well array allows profiling of the mutation status of 2 samples, while each 384-well format array allows mutation profiling of 8 samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments。
人大腦(GBM / CNS)癌癥qBiomarker體細(xì)胞突變PCR芯片是一個翻譯研究工具,用于快速,準(zhǔn)確,全面剖析人類GBM /前體細(xì)胞突變的中樞神經(jīng)系統(tǒng)癌癥的基因:BRAF,CTNNB1 /β-連環(huán)蛋白,EGFR, IDH1, IDH2, KRAS, NF2, NRAS, PIK3CA, and PTEN。這些突變保證廣泛的研究,以提高致癌作用的理解和鑒定潛在的藥物靶點。已有許多研究通過單個和多個體細(xì)胞突變狀態(tài)信息鑒定關(guān)鍵信號轉(zhuǎn)導(dǎo)中斷。例如,EGFR和KRAS基因的突變狀態(tài)可以預(yù)測某些藥物針對這些分子的生理反應(yīng)。人類GBM/CNS癌癥qBiomarker體細(xì)胞突變PCR芯片以其全面的內(nèi)容覆蓋范圍，用于研究GBM/CNS癌癥的環(huán)境突變且有潛力用于發(fā)現(xiàn)靶向藥物的生物標(biāo)記和驗證這些癌癥和其他這些突變已確定的癌癥。這個芯片包含37個DNA突變序列用于檢測最頻繁的，功能性驗證，在人類GBM/CNS癌癥顯著突變。這些突變的選擇根據(jù)全面的體細(xì)胞突變數(shù)據(jù)庫和同行評審的科學(xué)文獻(xiàn)，來自7800多個CNS癌癥樣本(包括6850份神經(jīng)膠質(zhì)瘤樣本)發(fā)生最頻繁重復(fù)編譯的體細(xì)胞突變。每個96孔芯片可以分析2個樣品的突變狀態(tài)，每個384孔芯片可以對 8個樣本進(jìn)行突變分析。簡單的產(chǎn)品模式和操作程序讓任何一個具備實時定量PCR儀的實驗室都可進(jìn)行常規(guī)的體細(xì)胞突變分析。BRAF: 1 Assay
The most important BRAF mutation in brain cancer leads to increased kinase activity, the p. V600E mutation.
CTNNB1: 5 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
EGFR: 4 Assays
The most frequently identified EGFR mutations include P-loop and activation loop point mutations, kinase domain deletions, and insertion mutations.
IDH1: 5 Assays
Most of these mutations abolish magnesium binding and alters the enzyme's activity to convert alpha-ketoglutarate into R(-)-2-hydroxyglutarate instead of isocitrate into alpha-ketoglutarate.
IDH2: 3 Assays
These mutations all lie in the substrate binding domain, and one (p.R140Q) is associated with D-2-hydroxyglutaric aciduria.
KRAS: 2 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
NF2: 1 Assay
NF2 is similar to some members of the ERM (ezrin, radixin, moesin) family of proteins and links cell-surface proteins with cytoskeletal components and proteins involved in cytoskeletal dynamics. Mutations in this gene are associated with neurofibromatosis type II which is characterized by nervous system and skin tumors and ocular abnormalities.
NRAS: 1 Assay
The most important NRAS mutation in brain cancer occurs at codon 61.
PIK3CA: 3 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
PTEN: 12 Assays
The most commonly detected PTEN loss-of-function mutations are due to either truncation (p.R233* and p.R130*) or point mutations causing phosphatase inactivation (p.R130 and p.R173 mutations).
View a table of the mutations, associated COSMIC IDs and assay numbers, by clicking “Mutation Table” above on the right.

工作原理：

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

 

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS?


姓名
電話號碼
電子郵箱
公司名稱
地址
留言*
 
驗證碼
提交